Xcelerate (XCRT) Q1 2025 earnings summary

Executive summary

• Q1 revenue declined YoY, while gross profit increased and operating loss narrowed; cash fell to $93,131 at quarter-end.

• A $2.218M working-capital deficit and insufficient expected operating cash flow prompted a substantial-doubt going-concern disclosure.

Financial highlights

• Q1 revenue was $646,509 vs. $811,391 YoY; cost of sales was $357,906 vs. $666,381, and gross profit was $288,603 vs. $145,010.

• Operating expenses were $404,709 vs. $397,477; operating loss narrowed to $116,106 from $252,467.

• Consolidated net loss was $154,440 vs. $195,721; net loss attributable to the parent was $107,960 vs. $195,721.

• Total assets were $1.639M and total liabilities $3.003M at March 31, 2025, compared with $1.680M and $2.889M at year-end 2024.

Outlook and guidance

• Strategic focus remains on developing medical technology and virtual health services, and consumer health and beauty products; licensing opportunities may be pursued when available.

• Additional funding is required; alternative financing sources are being explored, including potential securities sales and short-term loans, until operations become profitable.